NEW YORK (GenomeWeb) – BG Medicine today reported third quarter revenues of $334,000, down 52 percent from $695,000 in the third quarter of 2014.

The decline was due to a drop in product revenues from sales of the company's BGM Galectin-3 test, which fell to $274,000 in the quarter, down 59 percent from $669,000 in Q3 2014. Product fee revenues were up 57 percent to $60,000 compared to $26,000 in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.